Quetiapine for insomnia: A review of the literature.

  title={Quetiapine for insomnia: A review of the literature.},
  author={Sarah L. Anderson and Joseph P. Vande Griend},
  journal={American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists},
  volume={71 5},
  • Sarah L. AndersonJoseph P. Vande Griend
  • Published 1 March 2014
  • Psychology, Medicine
  • American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
PURPOSE The safety and efficacy of quetiapine for the treatment of insomnia in adults are reviewed. SUMMARY Quetiapine was developed for the treatment of psychiatric disorders, but its antagonism of histamine H1- and serotonin type 2A receptors has the added effect of causing sedation. As such, quetiapine is widely used off-label as a treatment for insomnia. Due to quetiapine's potential adverse effects, guidelines for the treatment of insomnia have recommended the drug's use only in patients… 

Tables from this paper

Quetiapine as a Potential Treatment for Insomnia: The Road Ahead

  • C. Cho
  • Psychology, Medicine
    Chronobiology in Medicine
  • 2022
Quetiapine is recommended for treating insomnia in the elderly not only because of the vulnerability and risk of side effects associated with sedative-hypnotics, but also because of its sedative action.

Prescription Dose Analysis of Quetiapine in the Elderly and Insomnia

In the case of primary insomnia, quetiapine dose prescribed in the elderly patient group is higher than that in the non-elderly patient group, which is a relatively low dose prescribed compared to schizophrenia and bipolar disorder.

Evaluation of the use of low-dose quetiapine and the risk of metabolic consequences: A retrospective review

There may be negative metabolic consequences with the use of low-dose quetiapine in patients with sleep disturbances and routine prescribing of low doses for sleep as a first-line medication should be avoided.

Does Combining Aripiprazole With Other Antipsychotics Worsen Psychosis?

  • N. Mahgoub
  • Psychology, Medicine
    Journal of clinical psychopharmacology
  • 2015
There is a clear rise in the OL use of low doses of quetiapine and mirtazapine in psychiatric patients and in individuals without serious psychiatric comorbidity, presumably to improve night-time sleep.

Pharmacologic Treatment Options for Insomnia in Patients with Schizophrenia

Overall, this review confirmed that there are a few evidence-based options to treat insomnia in patients with schizophrenia, including selecting a more sedating second-generation antipsychotic such as paliperidone, or adding melatonin or eszopiclone.

Quetiapine withdrawal: A systematic review

Clinicians should be alert to the possibility of quetiapine withdrawal in individuals who present with somatic symptoms or choreiform movements, and large prospective studies are required to clarify this association.

Pharmacotherapeutic options for treatment of insomnia

The pharmacotherapy of insomnia and the drugs under development for the treatment of insomnia are described and potential agents under investigations are targeting mechanisms and pathways including histamine (H 1 ) receptor, melatonin, and orexin receptors.

Off-Label Prescriptions of Low-Dose Quetiapine and Mirtazapine for Insomnia in The Netherlands

There are only limited data supporting the use of low doses of quetiapine in patients suffering from insomnia, and case reports describe restless legs syndrome, akathisia, and hepatotoxicity for low-dose quetuapine and mirtazapine.

Treatment of chronic insomnia disorder in menopause: evaluation of literature

Although a variety of interventions are shown to be helpful in improving sleep in menopause, there is a need for well-designed head-to-head trials with uniform outcome measures.



Safety of Low Doses of Quetiapine When Used for Insomnia

Using low-dose quetiapine for insomnia is not recommended based on limited data and potential safety concerns, and serious adverse events identified included fatal hepatotoxicity, restless legs syndrome, akathisia, and weight gain.

Quetiapine for Insomnia in Parkinson Disease: Results From an Open-Label Trial

It is suggested that quetiapine may be a safe and effective treatment of insomnia in PD patients and double-blind studies will probably confirm these findings.

Metabolic Consequences of Using Low-Dose Quetiapine for Insomnia in Psychiatric Patients

Despite the low doses typically used when quetiapine is prescribed for insomnia, metabolic adverse effects can occur and should be considered in the overall benefit to risk analysis.

Quetiapine for primary insomnia: a double blind, randomized controlled trial.

Quetiapine at 25 mg at night did show a trend for improvement of TST and reduced SL in primary insomnia with few side effects but not reaching statistical significance, and a study with a larger sample size is needed to demonstrate its efficacy.

Quetiapine in the Treatment of Sleep Disturbances Associated with Addictive Conditions: A Retrospective Study

The classical option of using sedating–hypnotic drugs to treat insomnia in polydrug users presents objections: the tolerance associated to high doses of benzodiacepines chronic abuse in many drug addicts obliges the clinician to use high doses in acute detoxificaton and the following de-habituation.

Drugs used to treat insomnia in 2002: regulatory-based rather than evidence-based medicine.

The present analysis suggests that the identified trends in the pharmacologic treatment of insomnia have continued and that antidepressants were used as frequently as insomnia drugs for the Treatment of insomnia in 2002.

Quetiapine augmentation in treatment-resistant depression: a naturalistic study

Preliminary data indicate that quetiapine add-on therapy appears to have beneficial effects in the treatment of patients with TRD.

A randomized, double-blind, and placebo-controlled trial of quetiapine augmentation of fluoxetine in major depressive disorder

Mixed-effects regression showed that quetiapine plus fluoxetine did not achieve 50% reduction in the Montgomery–Åsberg Depression Rating Scale score or improvement in Hamilton Anxiety Scale, Clinical Global Improvement (CGI)-Severity, and CGI-Improvement scores sooner than the fluxetine plus placebo group; however both groups improved in all scores over time.

A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II).

Quetiapine (300 or 600 mg/d), but not paroxetine, was more effective than placebo for treating acute depressive episodes in bipolar I and II disorder.